通过选择性抑制HDAC6来挑战三阴性乳腺癌:新的上限组识别,结构-活动关系,计算和生物研究
Simona Barone1, Ivana Bello1, Anna Guadagni1
1Department of Pharmacy, Department of Excellence, 2023-2027, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy.
European journal of medicinal chemistry
|April 27, 2025
概括
新的螺旋融合化合物可以选择性地抑制素脱乙酶6 (HDAC6),这是攻击性三阴性乳腺癌 (TNBC) 的关键标. 这些强效的抑制剂降低了癌细胞的活力和迁移,为TNBC提供了一个有前途的新疗法策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 三重阴性乳腺癌 (TNBC) 是高度侵略性和侵入性的.
- 表观遗传修饰在TNBC进展中发挥作用.
- 基斯脱乙酶6 (HDAC6) 是乳腺癌的潜在治疗点.
研究的目的:
- 开发用于TNBC治疗的新型,强效和选择性HDAC6抑制剂.
- 研究这些抑制剂在TNBC细胞中的作用机制.
- 在临床前模型中评估这些化合物的治疗潜力.
主要方法:
- 基于结构的药物设计和螺旋融合化合物的优化.
- 在体外和基于细胞的测试来评估HDAC6抑制和选择性.
- 使用MDA-MB-231 TNBC细胞进行细胞活力,细胞亡和迁移测定.
- 研究自机械在细胞死亡中的参与.
主要成果:
- 新型螺旋融合化合物23c和24c被确定为强效和选择性的HDAC6抑制剂.
- 在MDA-MB-231细胞中,HDAC6的mRNA表达升高.
- 化合物23c和24c降低了细胞活力,并抑制了MDA-MB-231细胞的迁移.
- 自机器参与了由这些化合物诱导的细胞死亡.
结论:
- 在TNBC的进展中,HDAC6起着至关重要的作用.
- 新型螺旋融合的HDAC6抑制剂显示出显著的临床前疗效.
- 这些发现为开发针对TNBC的新HDAC6向疗法提供了坚实的基础.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


